Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia

Medical Clinics of North America

Volumn 88, Issue 2, 2004, Pages 281-308

  Lam, John S ^a   Cooper, Kimberly L ^b,c   Kaplan, Steven A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Irving Pavilion ^*  (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; DOXAZOSIN; INDORAMIN; LONG ACTING DRUG; PHENOXYBENZAMINE; PRAZOSIN; SHORT ACTING DRUG; TERAZOSIN;

ANAMNESIS; BENIGN TUMOR; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; EVALUATION; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HYDROTHERAPY; LABORATORY TEST; LASER SURGERY; MICROWAVE THERAPY; PHYSICAL EXAMINATION; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROSTATECTOMY; REVIEW; STENT; SURGICAL TECHNIQUE; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; TREATMENT INDICATION; TUMOR DIAGNOSIS;

EID: 1242292261     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(03)00147-0     Document Type: Review

References (90)

1. Garraway W.M., Collins G.N., Lee R.J. High prevalence of benign prostatic hypertrophy in the community. Lancet. 338:1991;469-471.
2. Oesterling J.E. Benign prostatic hyperplasia: medical and minimally invasive treatment options. N Engl J Med. 332:1995;99-109.
3. McConnell J.D., Barry M.J., Bruskewitz R.C. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin. 8:1994;1-17.
4. Bruskewitz R. Medical management of BPH in the US. Eur Urol. 36:(suppl 3):1999;7-13.
5. McNeal J.E. Normal histology of the prostate. Am J Surg Pathol. 12:1988;619-633.
6. Partin A.W., Oesterling J.E., Epstein J.I., Horton R., Walsh P.C. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 145:1991;405-409.
7. Roehrborn C.G., McConnell J.D. Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Walsh P.C., Retik A.B., Vaughan E.D. Jr., Wein A.J. Campbell's urology. 8th edition:2002;1297-1336 WB Saunders, Philadelphia.
8. Barry M.J., Cockett A.T., Holtgrewe H.L., McConnell J.D., Sihelnik S.A., Winfield H.N. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 150:(2 pt 1):1993;351-358.
9. Sciarra A., D'Eramo G., Casale P., Loreto A., Buscarini M., Di Nicola S., et al. Relationship among symptom score, prostate volume, and urinary flow rates in 543 patients with and without benign prostatic hyperplasia. Prostate. 34:1998;121-128.
10. Barry M.J., Fowler F.J. Jr., O'Leary M.P., Bruskewitz R.C., Holtgrewe H.L., Mebust W.K., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 148:1992;1549-1557. 1564.
11. Roehrborn C.G., Girman C.J., Rhodes T., Hanson K.A., Collins G.N., Sech S.M., et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology. 49:1997;548-557.
12. Bissada N.K., Finkbeiner A.E., Redman J.F. Accuracy of preoperative estimation of resection weight in transurethral prostatectomy. J Urol. 116:1976;201-202.
13. Jepsen J.V., Bruskewitz R.C. Comprehensive patient evaluation for benign prostatic hyperplasia. Urology. 51:(suppl 4):1998;13-18.
14. Mebust W.K., Holtgrewe H.L., Cockett A.T., Peters P.C. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 141:1989;243-247.
15. Roehrborn C.G., McConnell J.D., Lieber M., Kaplan S., Geller J., Malek G.H., et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 53:1999;473-480.
16. Gormley G.J., Stoner E., Bruskewitz R.C., Imperato-McGinley J., Walsh P.C., McConnell J.D., et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
17. Wasson J.H., Reda D.J., Bruskewitz R.C., Elinson J., Keller A.M., Henderson W.G. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med. 332:1995;75-79.
18. Hieble J.P., Caine M., Zalaznik E. In vitro characterization of the α-adrenoceptors in human prostate. Eur J Pharmacol. 107:1985;111-117.
19. 1-adrenoceptor antagonists. Eur Urol. 36:(suppl 1):1999;35-41. 65.
20. 1-adrenoceptors: consensus update. Pharmacol Rev. 47:(2):1995;267-270.
21. 1- adrenoceptors and uroselectivity. Prostate. 30:1997;202-215.
22. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 36:1999;1-13.
23. Caine M., Perlberg S., Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 50:1978;551-554.
24. Hedlund H., Andersson K.E., Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol. 130:1983;275-278.
25. Roehrborn C.G., Van Kerrebroeck P.E., Nordling J. Safety and efficacy of alfuzosin 10 mg once daily: a pooled analysis of three double-blind placebo-controlled studies. [abstract 1045] J Urol. 167:(suppl 4):2002;265-266.
26. Jardin A., Bensadoun H., Delauche-Cavalier M.C., Attali P. Alfuzosin for treatment of benign prostatic hyperplasia. The BPH-ALF Group. Lancet. 337:1991;1457-1461.
27. Buzelin J.M., Roth S., Geffriaud-Ricouard C., Delauche-Cavallier M.C. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur Urol. 31:1997;190-198.
28. Stott M.A., Abrams P. Indoramin in the treatment of prostatic bladder outflow obstruction. Br J Urol. 67:1991;499-501.
29. Lepor H., Auerbach S., Puras-Baez A., Narayan P., Soloway M., Lowe F., et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 148:1992;1467-1474.
30. Brawer M.K., Adams G., Epstein H. Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med. 2:1993;929-935.
31. Roehrborn C.G., Oesterling J.E., Auerbach S., Kaplan S.A., Lloyd L.K., Milam D.E., et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology. 47:1996;159-168.
32. Lepor H., Williford W.O., Barry M.J., Brawer M.K., Dixon C.M., Gormley G., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Group. N Engl J Med. 335:1996;533-539.
33. Chapple C.R., Carter P., Christmas T.J., Kirby R.S., Bryan J., Milroy E.J., et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol. 74:1994;50-56.
34. Fawzy A., Braun K., Lewis G.P., Gaffney M., Ice K., Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol. 154:1995;105-109.
35. Gillenwater J.Y., Conn R.L., Chrysant S.G., Roy J., Gaffney M., Ice K., et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol. 154:1995;110-115.
36. 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol. 76:1995;325-336.
37. 1A -adrenoceptor antagonist: a meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 29:1996;155-167.
38. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 51:1998;892-900.
39. Narayan P., Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol. 160:1998;1701-1706.
40. Walsh P.C., Madden J.D., Harrod M.J., Goldstein J.L., MacDonald P.C., Wilson J.D. Familial incomplete hermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 291:1974;944-949.
41. Siiteri P.K., Wilson J.D. Dihydrotestosterone in prostatic hypertrophy: the formation and content of dihydrotestosterone in the hypertrophic prostate of men. J Clin Invest. 49:1970;1737-1745.
42. Peters C.A., Walsh P.C. The effect of nafarelin acetate, a luteinizing-hormone releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 317:1987;599-604.
43. McConnell J.D., Bruskewitz R., Walsh P., Andriole G., Lieber M., Holtgrewe H.L., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
44. Roehrborn C.G., Boyle P., Bergner D., Gray T., Gittelman M., Shown T., et al. Serum prostate-specific antigen and prostate volume predict long-term outcome in symptoms and flow rate: results of a 4-year, randomized trial comparing finasteride vs placebo. PLESS Study Group. Urology. 54:1999;662-669.
45. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434-41.
46. Boyle P., Siami P., Wachs B.H., Roehrborn C.G., Andriole G., Nickel C. Effect of dutasteride on the risk of acute urinary retention and the need for surgical treatment. [abstract 1479] J Urol. 167:(suppl 4):2002;372.
47. McConnell J.D. The long-term effects of medical therapy on the progression of BPH: results from the MTOPS trial. [abstract 1042] J Urol. 167:(suppl 4):2002;265.
48. Lowe F.C. Phytotherapy in the management of benign prostatic hyperplasia. Urology. 58:(6 suppl 1):2001;71-76.
49. de Tejada I.s., Garvey D.S., Schroeder J.D., Shelekhin T., Lette L.G., Fernandez A., et al. Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists as potential agents for the treatment of impotence. J Pharmacol Exp Ther. 290:1999;121-128.
50. Takeda M., Tang R., Shapiro E., Burnett A.L., Lepor H. Effects of nitric oxide on human and canine prostates. Urology. 45:1995;440-446.
51. Langenstroer P., Tang R., Shapiro E., Divish B., Opgenorth T., Lepor H. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J Urol. 150:(2 pt 1):1993;495-499.
52. Kobayashi S., Tang R., Wang B., Opgenorth T., Langenstroer P., Shapiro E., et al. Binding and functional properties of endothelin receptor subtypes in the human prostate. Mol Pharmacol. 45:1994;306-311.
53. Bruskewitz R.C., Reda D.J., Wasson J.H., Barrett L., Phelan M. Testing to predict outcome after transurethral resection of the prostate. J Urol. 157:1997;1304-1308.
54. Hakenberg O.W., Pinnock C.B., Marshall V.R. Does evaluation with the International Prostate Symptom predict the outcome of transurethral resection of the prostate? J Urol. 158:1997;94-99.
55. Zwergel U., Wullich B., Lendenmeir U., Rohde V., Zwergel T. Long-term results following transurethral resection of the prostate. Eur Urol. 33:1998;476-480.
56. Holtgrewe H.L. Transurethral prostatectomy. Urol Clin North Am. 22:1995;357-368.
57. Cattolica E.V., Sidney S., Sadler M.C. The safety of transurethral prostatectomy: a cohort study of mortality in 9,416 men. J Urol. 158:1997;102-104.
58. Nitti V.W., Kim Y., Combs A.J. Voiding dysfunction following transurethral resection of the prostate: symptoms and urodynamic findings. J Urol. 157:1997;600-603.
59. Cabelin M.A., Te A.E., Kaplan S.A. Transurethral vaporization of the prostate: current techniques. Curr Urol Rep. 1:2000;116-123.
60. Riehmann M., Knes J.M., Heisey D., Madsen P.O., Bruskewitz R.C. Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology. 45:1995;768-775.
61. Yang Q., Peters T.J., Donovan J.L., Wilt T.J., Abrams P. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis randomized controlled trials. J Urol. 165:2001;1526-1532.
62. Costello A.J., Kabalin J.N. Side-firing neodymium:YAG laser prostatectomy. Eur Urol. 35:1999;138-146.
63. Chertin B., Moriel E.Z., Hadas-Halperin I., Abu-Arafah W., Lupa S., Zilberman M., et al. Laser prostatectomy: long-term follow-up of 303 patients. Eur Urol. 35:1999;285-288.
64. Malek R.S., Kuntzman R.S., Barrett D.M. High power potassium-titanyl- phosphate laser vaporization prostatectomy. J Urol. 163:2000;1730-1733.
65. Muschter R., Whitfield H. Interstitial laser therapy of benign prostatic hyperplasia. Eur Urol. 35:1999;147-154.
66. Le Duc A., Gilling P.J. Holmium laser resection of the prostate. Eur Urol. 35:1999;155-160.
67. Blute M.L. Transurethral microwave thermotherapy: minimally invasive therapy for benign prostatic hyperplasia. Urology. 50:1997;163-166.
68. de la Rosette J.J., d'Ancona F.C., Debruyne F.M. Current status of thermotherapy treatment of the prostate. J Urol. 157:1997;430-438.
69. de Wildt M.J., Hubregtse M., Ogden C., Carter S.S., Debruyne F.M., De la Rosette J.J. A 12-month study of the placebo effect in transurethral microwave thermotherapy. Br J Urol. 77:1996;221-227.
70. Djavan B., Marberger M. Minimally invasive procedures as an alternative to medial management for lower urinary tract symptoms of benign prostatic hyperplasia. Curr Opin Urol. 11:2001;1-7.
71. Djavan B., Roehrborn C.G., Shariat S., Ghawidel K., Marberger M. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. J Urol. 161:1999;139-143.
72. Kaplan S.A., Blute M., Bruskewitz R.C., Larson T.R., Utz W., Ugarte R., et al. Long term efficacy and durability in 345 patients treated with transurethral microwave thermotherapy for benign prostatic hyperplasia: five year results. [abstract 1153] J Urol. 167:(suppl 4):2002;292.
73. Naslund M., Perez-Marrero R., Roehrborn C.G., Bruskewitz R., Issa M.M. Intermediate term outcomes of TUNA for BPH: 36 month results of the TUNA vs TURP US randomized study. [abstract 1511] J Urol. 161:(suppl 4):1999;389.
74. Zlotta A.R., Schulman C.C., Giannakopoulos X. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of benign prostatic hyperplasia (BPH): clinical outcome after 5 years. [abstract 1204] J Urol. 165:(suppl 5):2001;293.
75. Madersbacher S., Schatzl G., Djavan B., Stulnig T., Marberger M. Long-term outcome of transrectal high-intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol. 37:2000;687-694.
76. de la Rosette J.J., Alivizatos G., Laguna M.P. Transurethral hot water balloon thermoablation. Curr Urol Rep. 2:2001;302-305.
77. Lam J.S., Volpe M.A., Kaplan S.A. Use of prostatic stents for the treatment of benign prostatic hyperplasia in high-risk patients. Curr Urol Rep. 2:2001;277-284.
78. Kaiser F.E., Morley J.E. Gonadotropins, testosterone, and the aging male. Neurobiol Aging. 15:1994;559-563.
79. Frankel S.J., Donovan J.L., Peters T.I., Abrams P., Dabhoiwala N.G., Osawa D., et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol. 51:1998;677-685.
80. Tubaro A., Polito M., Giambroni L., Famulari C., Gange E., Ostardo E. Sexual function in patients with LUTS suggestive of BPH. Eur Urol. 40:2001;19-22.
81. Vale J. Benign prostatic hyperplasia and erectile dysfunction: is there a link? Curr Med Res Opin. 16:(suppl 1):2000;s63-s67.
82. Rosen R, Altwein J, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7).
83. Leliefeld H.H., Stovelaar H.J., McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int. 89:2002;208-213.
84. Kinn A.C., Helmy-Dhejne C., Larsson J. Sexual function one year after transurethral prostatic resection: patients' own assessments. Scand J Urol Nephrol. 32:1998;33-35.
85. Tscoll R., Largo M., Poppinghaus E., Recker F., Subotic B. Incidence of erectile impotence secondary to transurethral resection of benign prostatic hyperplasia, assessed by preoperative and postoperative Snap Gauge tests. J Urol. 153:1995;1491-1493.
86. Roehrborn C.G., Issa M.M., Bruskewitz R.C., Naslund M.J., Oesterling J.E., Perez-Marrero R., et al. Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter US study. Urology. 51:1998;415-421.
87. Tsai Y.S., Lin J.S., Tong J.C., Tzai T.S., Yang W.H., Chang C.C., et al. Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: long-term durability with Prostcare. Eur Urol. 39:2001;688-692.
88. Rodrigues Netto N. Jr., Claro J de A., Cortado P.L. Ejaculatory dysfunction after transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia. J Endourol. 8:1994;217-219.
89. Marberger M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double blind, placebo controlled, multicenter study. PROWESS Study Group. Urology. 51:1998;677-686.
90. Andriole G.L., Guess H.A., Epstein J.I., Wise H., Kadmon D., Crawford E.D., et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group: Proscar Long-term Efficacy and Safety Study. Urology. 52:1998;195-201.